A Phase 2 interventional study of HRS-4729 Injection and Mazdutide in Type 2 Diabetes, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 11 under way, 4 of them phase 3. Diabetes Mellitus, Type 2 · Jiangsu HengRui Medicine Co., Ltd..
Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., this one is the 19th largest by planned enrollment, is one of 7 that started in 2026, is one of 15 in phase 2, reaches primary completion later than 8 of the 10 other live ones, and was the 79th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →8 of the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18–65 · Healthy volunteers
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18–59
Fujian Shengdi Pharmaceutical Co., Ltd. · Sites in China
Ages 18+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18+
Jiangsu HengRui Medicine Co., Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 80 across the 81 interventional studies. Of the 50 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Fujian Shengdi Pharmaceutical Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Fujian Shengdi Pharmaceutical Co., Ltd. is the lead sponsor of 66 studies on the registry; 24 are open to participants now.
7 of the studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd. that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060456Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin | 2027-02 |
| NCT07920939Phase 3Jiangsu HengRui Medicine Co., Ltd.Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes | 2027-10 |
| NCT07841860Fujian Shengdi Pharmaceutical Co., Ltd.A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-1596 Tablets in Healthy Participants With a Single Dose and in Obese Participants With Multiple Doses | 2026-12 |
| NCT07472725Jiangsu HengRui Medicine Co., Ltd.A Study Comparing Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-Dose Titration in Adults With Type 2 Diabetes Inadequately Controlled With Oral Antihyperglycemic Agents | 2026-12 |
| NCT07032688Jiangsu HengRui Medicine Co., Ltd.A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes | 2027-03 |
Add all 7 to your calendar (.ics) → With an account.
Among the 81 studies in Diabetes Mellitus, Type 2 by Jiangsu HengRui Medicine Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the efficacy and safety of HRS-4729 Injection in participants with type 2 diabetes who failed to achieve adequate glycemic control on diet and exercise alone or on a stable dose of metformin.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS-4729 Injection
Drug: HRS-4729 Injection
Drug: HRS-4729 Injection
Drug: HRS-4729 Injection
Drug: Mazdutide
Drug: Placebo
HRS-4729 Injection
Mazdutide
Placebo
Change From Baseline in HbA1c
Time frame: Baseline, Week 28
Percentage of Participants Reaching HbA1c <7.0%, ≤6.5%, and <5.7%
Time frame: Baseline, Week 28
Percent Change From Baseline in Body Weight
Time frame: Baseline, Week 28
Change From Baseline in Fasting Plasma Glucose
Time frame: Baseline, Week 28
TEAEs
Time frame: Baseline, Week 32
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Apr 2027, 6 months later.
Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 6 months is below that.
Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-4729
Fujian Shengdi Pharmaceutical Co., Ltd. →